EUVIMEDEUVIMED entdecken
Crossref

Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD

Clémence M Canivet iD, Charlotte Costentin, Katharina M Irvine, Adèle Delamarre, Adrien Lannes, Nathalie Sturm, Frederic Oberti, Preya J Patel, Thomas Decaens, Marie Irles-Depé, Isabelle Fouchard, Paul Hermabessière und 6 weitere

Hepatology · 2023-03 · 77 (3) · 920-930

DOI: 10.1002/hep.32665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology, online erschienen am 17.02.2023. Verfasst von Clémence M Canivet und 17 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hépato-Gastroentérologie et Oncologie Digestive , Centre Hospitalier Universitaire d'Angers , Angers , France. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: The European Association for the Study of the Liver (EASL) has recently proposed an algorithm for the diagnosis of advanced liver fibrosis. We aimed to evaluate the diagnostic accuracy of this algorithm in nonalcoholic fatty liver disease (NAFLD). Approach and Results: One thousand fifty‐one patients with NAFLD, liver biopsy, and four noninvasive tests (NITs; Fibrosis‐4 [FIB4], vibration controlled transient elastography [VCTE], FibroMeter, Fibrotest) were included. The enhanced liver fibrosis (ELF) score was available in 396 patients. A cohort of 230 patients from primary care/diabetes clinics had FIB4, VCTE, and ELF. Compared with the performance of single NITs, agreement between two NITs (FIB4 and VCTE, VCTE and patented serum tests) increased specificity and positive predictive value by 20%, thus justifying the sequential use proposed in the EASL algorithm. The FIB4/VCTE/FibroMeter and FIB4/VCTE/Fibrotest algorithms performed similarly, providing 85% diagnostic accuracy and a liver biopsy requirement rate of only 10%. The FIB4/VCTE/ELF algorithm performed similarly in the subgroup where ELF was available. Simulations of algorithm accuracies at different prevalence showed that positive predictive values rapidly increased, reaching a plateau above 75% starting at 15% prevalence. Negative predictive values remained higher than 90% up to 25% prevalence. The rate of liver biopsy requirement remained stable, increasing by only 5% between low and high prevalence settings. When the EASL algorithm was applied in the primary care/diabetes clinic cohort, liver biopsy requirement was only 3%, and the agreement among the three steps provided 75% positive predictive value. Conclusions: Our study validates the algorithm proposed by the EASL in its latest 2021 guidelines for the diagnosis of advanced fibrosis in the setting of NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseElasticity Imaging TechniquesHumansLiverLiver CirrhosisFibrosisAlgorithmsBiopsy

Autor:innen und Institutionen

  • Service d'Hépato-Gastroentérologie et Oncologie Digestive , Centre Hospitalier Universitaire d'Angers , Angers , France.
  • Laboratoire HIFIH, UPRES EA3859, SFR 4208 , Université d'Angers , Angers , France.
  • Université Grenoble Alpes, Institute for Advanced Biosciences , Research Center UGA/Inserm U 1209/CNRS 5309 , Grenoble , France.
  • Service d'Hépato-Gastroentérologie , Centre Hospitalier universitaire Grenoble-Alpes , La tronche , France.
  • Mater Research , The University of Queensland, Translational Research Institute , Woolloongabba, Brisbane , Queensland , Australia.
  • Centre for Liver Disease Research, Translational Research Institute , The University of Queensland , Woolloongabba, Brisbane , Queensland , Australia.

ORCID-Profile: Clémence M Canivet

Zitieren

APA

Canivet, C. M., Costentin, C., Irvine, K. M., Delamarre, A., Lannes, A., Sturm, N., Oberti, F., Patel, P. J., Decaens, T., Irles-Depé, M., Fouchard, I., Hermabessière, P., Roux, M., Barthelon, J., Calès, P., Powell, E. E., de Ledinghen, V., & Boursier, J. (2023). Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. Hepatology, 77(3), 920-930. https://doi.org/10.1002/hep.32665

Vancouver

Canivet CM, Costentin C, Irvine KM, Delamarre A, Lannes A, Sturm N, et al. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. Hepatology. 2023;77(3):920-930. doi:10.1002/hep.32665

BibTeX
@article{Canivet2023,
  author = {Canivet, Clémence M and Costentin, Charlotte and Irvine, Katharina M and Delamarre, Adèle and Lannes, Adrien and Sturm, Nathalie and Oberti, Frederic and Patel, Preya J and Decaens, Thomas and Irles-Depé, Marie and Fouchard, Isabelle and Hermabessière, Paul and Roux, Marine and Barthelon, Justine and Calès, Paul and Powell, Elizabeth E and de Ledinghen, Victor and Boursier, Jérôme},
  title = {Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD},
  journal = {Hepatology},
  year = {2023},
  volume = {77},
  number = {3},
  pages = {920--930},
  doi = {10.1002/hep.32665}
}
Kostenlos starten →